Collagen and glycosaminoglycans, such as hyaluronan and chondroitin sulfate, are the major components of bone extracellular matrix, and extracellular matrix composites are being evaluated for a wide range of clinical applications. The molecular and cellular effects of native and sulfatemodified glycosaminoglycans on osteocytes were investigated as critical regulators of bone remodeling. The effects of glycosaminoglycans on viability, necrosis, apoptosis, and regulation of gene expression were tested in two osteocyte-like cell lines, the murine MLO-Y4 and the rat UMR 106-01 cells. Glycosaminoglycans were non-toxic and incorporated by osteocytic cells. In MLO-Y4 cells, sulfation of glycosaminoglycans led to a significant inhibition of osteocyte apoptosis, 42% inhibition for highly sulfated chondroitin sulfate and 58% for highly sulfated hyaluronan, respectively. Cell proliferation was not affected. While treatment with highly sulfated chondroitin sulfate increased cell viability by 20% compared to the native chondroitin sulfate. In UMR 106-01 cells, treatment with highly sulfated hyaluronan reduced the receptor activator of nuclear factor-κB ligand/osteoprotegerin ratio by 58% compared to the non-sulfated form, whereas highly
Introduction
In populations where aging is associated with increased obesity and low physical activity, there is a growing need for biomaterials to replace bone tissue that has been destroyed by degeneration, trauma, tumors, or inflammation, ranging from autologous bone to conventional bone grafts and engineered bone tissue. 1 Because bone implants are characterized by a large variety of their structural composition, their curative potential is also wide. 2, 3 It is thus of great significance to define the optimal structural composition of the applied graft material and characterize the cellular response of the host tissue. [4] [5] [6] The most promising approach may be to utilize and modify components of the native extracellular matrix (ECM) in order to generate artificial functional matrices (artificial extracellular matrix (aECM)) for the use as bone implants. 7 The majority of bone is made of the ECM, which can be divided into an inorganic part of hydroxyapatite and an organic part that mainly consists of type I collagen (Coll) with embedded proteoglycans (PGs). PGs consist of a central protein core and peripheral glycosaminoglycan (GAG) chains that have repetitive disaccharide units. 8 The most abundant GAG in bone is chondroitin sulfate (CS), with smaller amounts of hyaluronan (HA) and dermatan sulfate. 9 Because the properties of the GAGs tend to dominate the properties of the entire PG molecule, research has focused on the development of GAG composites to increase implant bioactivity. 10 Until recently, osteocyte functions were poorly defined, but recent discoveries have underlined the multifactorial profile of these cells in orchestrating bone remodeling by regulating both osteoblast and osteoclast functions. 11 Furthermore, the regulatory role of osteocytes in calcium and phosphate metabolism mainly through the production of fibroblast growth factor 23 (FGF-23) 12 and its mechanosensory role 13 have been highlighted. Taking into account these newly discovered roles as well as the fact that osteocytes make up over 95% of the bone cells in the adult skeleton, the interactions between osteocytes and GAG composites are of key importance. We have recently investigated the effects of the degree of sulfation of GAGs on osteoclast and osteoblast function and signaling pathways and found that highly sulfated GAGs significantly inhibit various functions of bone-resorbing osteoclasts, while stimulating matrix formation in osteoblastic cells. [14] [15] [16] However, to our knowledge, there are no studies describing the effects of native or sulfated GAGs on osteocytes.
Here, we synthesized soluble GAG derivatives containing well-defined properties with respect to chain length and sulfation degree and analyzed their effects on osteocyte viability, proliferation, apoptosis, and expression of osteocyte-specific markers. We found that highly sulfated GAGs contributed to the phenotype of healthy, viable, and functional osteocytes as they inhibited ostocyte apoptosis in vitro and promoted an osteoblast-supporting gene expression profile.
Materials and methods

Preparation and characterization of GAGs
Native, high-molecular-weight HA was obtained from Aqua Biochem (Dessau, Germany). CS (a mixture of 70% chondroitin-4-sulfate and 30% chondroitin-6-sulfate) from porcine trachea was purchased from Kraeber (Ellerbek, Germany).
GAG modification and synthesis of derivatives
GAGs were prepared and characterized as previously described. [17] [18] [19] [20] [21] In brief, HA sulfates and oversulfated CS derivatives were prepared by sulfation reactions using the tetrabutylammonium salts of native HA and CS. Both highly sulfated hyaluronan (sHA) and highly sulfated chondroitin sulfate (sCS) containing approximately 13 wt% sulfur, corresponding to an average degree of sulfate groups per disaccharide repeating unit (DS S ) of 3.1, were sulfated using the SO 3dimethylformamide (DMF) complex.
Low-molecular-weight HA (HA LMW ) was prepared by a controlled thermal degradation of the native high-molecular-weight HA as reported. [17] [18] [19] [20] [21] The prepared GAG derivatives were characterized spectroscopically by 13 C-nuclear magnetic resonance spectroscopy, Fourier transform infrared spectroscopy, and estimation of the sulfur content using a conventional automatic elemental analyzer. 22 The GAG molecular weights were determined by gel-permeation chromatography analysis as described earlier. 17, 18 Cell culture of murine and rat osteocytes
The murine osteocyte-like cell line MLO-Y4 (kindly provided by Dr Lynda Bonewald, Kansas City, MO, USA) was cultured as previously described. 23, 24 Briefly, cells were cultured on collagencoated cell culture flasks (Greiner Bio-One, Frickenhausen, Germany) in alpha-modified essential medium (Biochrom, Berlin, Germany) with 10% fetal calf serum (FCS) (Biochrom), 1% penicillin/streptomycin (Gibco, Darmstadt, Germany), and 2 mM glutamine (Biochrom). Before treatment, cells were placed into serum-free media overnight.
The rat osteocyte-like cell line UMR-106 was kindly provided by Dr Ute Hempel (TU Dresden) and was cultured as previously described. 25 Briefly, cells were cultured on cell culture flasks (Greiner Bio-One) in alpha-modified essential medium (Gibco) with 10% FCS (Biochrom) and 1% penicillin/streptomycin (Gibco). Before treatment, cells were placed into serum-free media overnight.
Susceptibility to GAGs
UMR-106 cells were seeded on glass slides and incubated with fluorescent GAGs for up to 24 h to determine (1) whether osteocytes are susceptible to both the native and the highly sulfated GAGs, (2) where these GAGs localize in the cells, and (3) whether there are kinetic differences. After the incubation period, slides were stained for F-actin and cell nuclei as previously described. 14 Cells cultured without GAGs served as control.
Coculture of UMR-106 with RAW264.7 cells
The murine RAW264.7 cell line is a monocyte cell line with a differentiation potential toward mature osteoclasts. Murine RAW264.7 cells were purchased from American Type Culture Collection (ATCC) (Wesel, Germany) and cultured on cell culture flasks (Greiner Bio-One) in alpha-modified essential medium (Biochrom) with 10% FCS (PAA), 1% penicillin/streptomycin (Gibco), and 2 mM glutamine (Biochrom). Cells were cultivated up to 85% confluency before being passaged.
UMR-106 cells were plated at 2000 cells/well in 96-well plates and kept for 48 h. Before treatment, cells were placed into serum-free media overnight. Cells were treated with 200 µg/mL HA LMW , HA, sHA, CS, and sCS for 24 h, at which point the medium was removed and RAW264.7 cells were plated at 4000 cells/well. To initiate osteoclastogenesis, receptor activator of nuclear factor-κB ligand (RANKL) (50 ng/mL, R&D Systems, Minneapolis, MN, USA) was added. Medium was replaced every 2 days, and at the end of culturing, the cells were fixed and stained for tartrate-resistant acid phosphatase (TRAP) using a leukocyte acid phosphatase kit (Sigma Chemical Co., Seelze, Germany) as described previously. 26 Three or more nuclei containing TRAP-positive cells were considered osteoclasts and counted under a microscope.
Cell viability
Cell viability was assessed using a commercial assay (CellTiter-Blue; Promega, Mannheim, Germany) according to the manufacturer's instructions. MLO-Y4 cells were plated at 50,000 cells/ well in 96-well plates and kept for 48 h. Before treatment, cells were placed into starving media (0% FCS) overnight. Cells were treated with 200 µg/mL HA LMW , HA, sHA, CS, and sCS for 24 h, at which point the medium was removed and changed to fresh medium containing the resazurin dye. Viability was determined by the ability of living cells to convert resazurin dye into a fluorescent product within 2-4 h. Fluorescence intensity was quantified using FLUOstar Omega (560 Ex /590 Em nm, BMG Labtech).
Cell proliferation
Cell proliferation was assessed using a commercial assay (BrdU; Roche, Grenzach-Wyhlen, Germany) according to the manufacturer's instructions. MLO-Y4 cells were plated at 50,000 cells/ well in 96-well plates and kept for 48 h. Before treatment, cells were placed into starving media (0% FCS) overnight. Cells were treated with 200 µg/mL HA LMW , HA, sHA, CS, and sCS for 24 h while BrdU was added. During this labeling period, the pyrimidine analogue BrdU was incorporated in place of thymidine into the DNA of proliferating cells. After 24 h, the culture medium was removed, and the assay was resumed according to protocol. The reaction product was quantified by measuring the absorbance at 450 nm using FLUOStar Omega (BMG Labtech, Ortenberg, Germany).
Cell apoptosis
Cell apoptosis was assessed using a commercial assay (Caspase-Glo; Promega) according to the manufacturer's instructions. MLO-Y4 cells were plated at 20,000 cells/well in 96-well plates and kept for 48 h. Before treatment, cells were placed into starving media (0% FCS) overnight. Cells were treated with 200 µg/mL HA LMW , HA, sHA, CS, and sCS for 24 h at which point the medium was removed and the Caspase-Glo reagent was added, resulting in cell lysis, followed by caspase cleavage of the substrate and generation of a glow-type luminescent signal, produced by luciferase. Luminescence was proportional to the amount of caspase activity present and was measured after 60 min using the FLUOStar Omega luminometer.
RNA isolation, reverse transcriptase and quantitative real-time polymerase chain reaction
For the detection of messenger RNA (mRNA) expression levels, UMR-106 cells were cultured as described above with or without (control) the addition of 200 µg/mL GAGs, respectively. RNA was extracted using a High Pure RNA Isolation Kit from Roche. Then, 500 ng RNA was reverse transcribed using SuperScript ® II (Invitrogen), and a SYBR ® Green-based real-time polymerase chain reaction (PCR) under standard conditions was performed. PCR primers were generated with Primer3 and OligoAnalyzer 3.0 software. All applied primer sequences are given in Table 1 . The abundance of mRNA levels was calculated using the ΔΔCT method 27 and is presented as increases relative to an untreated or undifferentiated control.
Statistical analyses
All experiments were performed at least in triplicates and evaluated using one-way analysis of variance (ANOVA). Student's t-test was performed to compare native GAGs with modified GAGs. All results are presented as the mean ± standard deviation (SD); p values <0.05 were considered statistically significant.
Results and discussion
Osteocyte susceptibility to differentially sulfated GAGs UMR-106 and MLO-Y4 cells ingested both native and sulfated HA (Figure 1(a) -data for MLO-Y4 and data for UMR-106 are not shown). After 24 h, GAGs were detected in vesicles in the perinuclear region. This localization was observed earlier for the shorter, highly sulfated HA, where the first vesicles were found after 1 h, whereas vesicles of native HA did not appear before 6 h. This effect has been corroborated by the interactions between human mesenchymal stromal cells (MSC) and sulfated HA-containing collagen matrices where an upregulation of endocytic proteins was noted. 28 The fact that both forms of HA appeared intracellularly excludes the possibility that GAG sulfation results in impaired uptake that could affect all subsequent effects. A potential limitation of our study was the fact that the immunofluorescence experiments were conducted using only native and highly sulfated HA and not CS.
Sulfation of GAGs reduces osteocyte apoptosis
After establishing GAG localization in the perinuclear region of osteocytes, we examined the effect of GAG treatment on osteocyte apoptosis. Treatment for 24 h with highly sulfated GAGs at a concentration of 200 µg/mL led to a significant reduction in osteocyte apoptosis in MLO-Y4 cells. Treatment with sHA led to a 58% decrease in apoptosis when compared to HA (p < 0.001) ( Figure  1(b) ), whereas sCS reduced apoptosis by 42% when compared to its native product (p < 0.01) ( Figure  2 ). Native HA and CS tended to increase osteocyte apoptosis, but these results were not statistically significant. HA LMW had no significant effects on osteocyte apoptosis (data not shown). 
Sulfation of GAGs differentially regulate osteocyte viability, but not proliferation
The effects of highly sulfated GAGs on osteocyte viability and proliferation were assessed next. Neither native nor highly sulfated HA had any significant effect on osteocyte viability (Figure 1(c) ) and HA LMW had also no significant effect on osteocyte apoptosis (data not shown). Treatment with sCS increased cell viability by 20% compared to its native product (p < 0.001) ( Figure 2 ). Treatment with sHA did not significantly affect cell viability. Our data also indicate that treatment with GAGs both in their native and their highly sulfated form had a neutral effect on osteocyte proliferation (Figure 2(c) , data for CS shown). In summary, we observed an anti-apoptotic effect of highly sulfated HA and CS on osteocytes. Furthermore, treatment of osteocytes with sulfated CS, but not native GAGs, led to an enhancement of cell viability, whereas all GAGs had no significant effect on cell proliferation. Of note, treatment with HA LMW had no significant effect on osteocyte apoptosis and viability. It can thus be concluded that the degree of sulfation, rather than the monosaccharide composition of GAGs, determines biological functions. GAG sulfation inhibited apoptosis and enhanced viability. Thus, highly sulfated GAGs would represent suitable candidates for preclinical testing in appropriate animal models. We have already shown that GAG sulfation led to a significant inhibition of osteoclast differentiation and resorption 14 and supported osteoblast functions. 16 Extrapolation of our findings from in vitro to the in vivo situation suggests that sulfated GAGs could contribute to the phenotype of healthy, viable, and functional osteocytes, thus supporting our previous results on osteoclasts and osteoblasts. However, this needs to be formally tested in appropriate in vivo models.
GAG sulfation affects the expression of osteocytic genes
Since UMR-106 cells express genes such as sclerostin, RANKL, and connexin-43, we used these cells as a model to assess the effects of GAGs on the regulation of osteocytic gene expression. Exposure of UMR-106 cells to native GAGs resulted in a consistent downregulation of RANKL, which promotes osteoclastogenesis. Using a concentration of 200 µg/mL, we found that sHA downregulated the expression of RANKL by 50% in comparison with its native form (p < 0.05) (Figure 3(a) ), whereas treatment with sCS did not significantly influence RANKL expression (Figure 4(a) ). Treatment with GAGs had a neutral effect on the expression of osteoprotegerin (OPG) (Figures 3(b) and 4(b) ), but led to a significant downregulation of the RANKL/OPG ratio. In particular, sHA reduced the RANKL/OPG ratio by 58% in comparison with its native form (Figure 3 (c)) (p < 0.05), an effect also seen for sCS (Figure 4(c) ). Furthermore, the expression of SOST, the gene encoding sclerostin, was reduced by both highly sulfated GAGs when compared to their native forms (−50%, p = 0.06 for HA and −45%, p < 0.05 for CS, respectively) (Figure 4(c) and (d) ).
By contrast, the expression of genes enhancing osteoblast and osteocyte differentiation, such as BMP-2, was found to be upregulated twofold by highly sulfated HA as compared to its native form (p < 0.05) (Figure 3(e) ). Treatment with sCS did not lead to a significant increase in BMP-2 expression (Figure 4(e) ). The expression of GAJ-1, the gene encoding connexin 43, an important gap junction protein in osteocytes, was downregulated by sHA as compared to its native form (p < 0.05) Ctrl: control; HA: native hyaluronan; sHA: highly sulfated hyaluronan; RANKL: receptor activator of nuclear factor-κB ligand; OPG: osteoprotegerin; SOST: sclerostin; BMP-2: bone morphogenetic protein 2; GAJ-1: gap junction membrane channel protein alpha 1 or connexin 43; SD: standard deviation; PCR: polymerase chain reaction. *p < 0.05, **p < 0.01, and ***p < 0.001; Student's t-test versus treatment with native GAG.
( Figure 3(f) ). Neither CS nor its sulfated form influenced GAJ-1 expression (Figure 4(f) ). HA LMW had no significant effects on the expression of osteocyte markers (data not shown).
When considering osteocyte gene expression, our data indicated that sHA significantly reduces the expression of RANKL and both highly sulfated HA and CS downregulate the RANKL/OPG ratio. In bone homeostasis, the expression of RANKL and OPG is balanced resulting in physiological bone remodeling. An overexpression of RANKL is observed in estrogen deficiency, 29 systemic glucocorticoid exposure, and active inflammatory processes in rheumatoid arthritis, 30 skeletal malignancies such as multiple myeloma, 31 and bone metastases. 32 All these conditions are characterized by excessive bone loss, implying that the upregualtion of the RANKL/OPG ratio promotes excessive bone resorption. Thus, it may be envisaged that treatment of osteocytes with highly sulfated GAGs suppresses their paracrine ability to support osteoclast differentiation and resorption.
Furthermore, treatment with highly sulfated GAGs led to a significant reduction in SOST and regulated BMP-2 as well as GAJ-1, the gene encoding connexin 43. To this end, inhibition of Ctrl: control; CS: native chondroitin sulfate; sCS: highly sulfated chondroitin sulfate; RANKL: receptor activator of nuclear factor-κB ligand; OPG: osteoprotegerin; SOST: sclerostin; BMP-2: bone morphogenetic protein 2; GAJ-1: gap junction membrane channel protein alpha 1 or connexin 43; SD: standard deviation; PCR: polymerase chain reaction. *p < 0.05, **p < 0.01, and ***p < 0.001; Student's t-test versus treatment with native GAG. sclerostin and upregulation of connexin 43 and BMP-2 through GAGs could contribute to the phenotype of viable and functional osteocytes and osteoblasts.
Coculture of UMR-106 with RAW264.7 cells
After having found a considerable regulation of the RANKL/OPG ratio by highly sulfated GAGs, we performed cocultures of osteocytes/osteoclasts. Treatment with native HA and HA LMW led to an inhibition of osteoclastogenesis by 40%, whereas highly sulfated HA and both forms of CS tended to enhance osteoclastogenesis; nevertheless, these results did not reach a level of statistical significance.
Despite its strength, our study has potential limitations. We observed a regulation of RANKL but not OPG through GAGs, and in contrast to our expectations, it was the native and not the sulfated form of HA that led to an inhibition of osteoclastogenesis. We hypothesize that the addition of RANKL in a concentration of 50 ng/mL in a latter phase of the coculture might have dominated the effect of GAGs on osteocytes or alternatively that RANKL directly bound to OPG influencing the results. Another limitation is the fact that both cell lines used possess at the most an osteocyte-like phenotype, in that the MLO-Y4 cells represent the osteocyte morphology and the UMR-106 cells represent the osteocyte gene expression, while neither cell line combines both characteristics as primary human osteocytes would. In this context, one can only hypothesize as to whether the results gained by experiments using osteocyte-like cell lines can be extrapolated to the in vivo environment.
Conclusion
Based on our data, GAGs inhibit osteocyte apoptosis and promote osteocyte viability while maintaining a physiological RANKL/OPG ratio. These results are in accordance with the proosteoblastic and anti-osteoclastic effects of sulfated GAGs that we previously reported. The present data confirm these functions on osteocytes, which represent the most abundant cell type and indicate a promising potential as a component of diverse biomaterials. However, our conclusions at this time are based only on in vitro data and require in vivo validation.
